Clinical Trial Update: 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) [Phase 3]

View source ↗

Summary

This Phase 3 52-week efficacy and safety study of ibodutant in women with irritable bowel syndrome with diarrhea was terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Diarrhea

Drugs mentioned

• ibodutant (ibodutant)

Snippet

Sponsor: Menarini Group | Conditions: Irritable Bowel Syndrome With Diarrhea | Phase 3 | Status: TERMINATED | Results posted: 2017-01-18